Polycystic ovary syndrome and the postmenopausal woman

Journal of the British Menopause Society

Volumn 12, Issue 4, 2006, Pages 143-148

  Ireland, Karen ^a   Child, Tim ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cardiovascular disease; Insulin resistance; Menopause; Metabolic syndrome; Polycystic ovary syndrome

Indexed keywords

CLOMIFENE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; METFORMIN; PLACEBO; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; ENDOMETRIUM CARCINOMA; FEMALE INFERTILITY; GENOTYPE PHENOTYPE CORRELATION; HERITABILITY; HUMAN; HYPERANDROGENISM; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; META ANALYSIS; METABOLIC DISORDER; MORTALITY; OSTEOPOROSIS; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; POSTMENOPAUSE; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW;

BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; OSTEOPOROSIS; POLYCYSTIC OVARY SYNDROME; POSTMENOPAUSE;

EID: 33845874621     PISSN: 13621807     EISSN: 17404568     Source Type: Journal    
DOI: 10.1258/136218006779160580     Document Type: Review

References (41)

1. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet 1999;353:571-80
2. Matthews KA, Meilahn E, Kulle LH, et al. Menopause and risk factors for coronary heart disease. New Engl J Med 1989;321:641-6
3. Lindheim SR, Presser SC, Ditkoff EC, et al. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of progestin. Fertil Steril 1993;60:664-6
4. Portaluppi F, Pansini F, Manfredini R, Mollica G. Relative influence of menopausal status, age, and body mass index on blood pressure. Hypertension 1997;29:976-9
5. Rees M, Purdie DW, eds. Management of the Menopause (4th edn). London: British Menopause Society Publications Ltd and Royal Society of Medicine Press, 2006
6. Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome. Hum Reprod 2004;19:41-7
7. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endrocrinol Metab 1998;83:3078-82
8. Asuncion M, Calvo RM, San Millan JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endrocrinol Metab 2000;85:2434-8
9. Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endrocrinol Metab 2004;89:2745-9
10. Margolin E, Zhornitzki T, Kopernik G, et al. Polycystic ovary syndrome in post-menopausal women - marker of the metabolic syndrome. Maturitas 2005;50:331-6
11. Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries - a common finding in normal women. Lancet 1988;16:870-2
12. Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol 1999;51:779-86
13. Birdsall MA, Farquhar CM. Polycystic ovaries in pre and post menopausal women. Clin Endocrinol 1996,44:269-76
14. Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab 2003;14:365-70
15. Ehrmann DA. Polycystic ovary syndrome. New Engl J Med 2005;352:1223-36
16. Pasquali R. Obesity and androgens: facts and perspectives. Fertil Steril 2006;85:1319-40
17. Kahsar-Miller MD, Nixon C, Boots LR, et al. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril 2001;75:53-8
18. Legro RS, Driscoll D, Strauss JF, et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA 1998;95:14956-60
19. Grundy SM, Brewer HB Jr, Cleeman JI, et al. American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8
20. Sharpless JL. Polycystic ovary syndrome and the metabolic syndrome. Clin Diabetes 2003;21:154-61
21. Glueck CJ, Papanna R, Wang P, et al. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003;52:908-15
22. Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-6
23. Ehrmann DA, Liljenquist DR, Kasza K, et al. PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:48-53
24. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-9
25. Peppard HR, Iuorno MJ, Marfori J, Nestler JE. Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care 2001;24:1050-2
26. Glueck CJ, Wang P, Kobayashi S, et al. Mettormin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002;77:520-5
27. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Systematic Rev 2003;(3):CD003053
28. Stadtmauer LA, Wong BC, Oehninger S. Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome - beyond ovulation induction. Hum Reprod 2002;17:3016-26
29. Pierpoint T, McKeigue PM, Issacs AJ, et al. Mortality of women with polycystic ovary syndrome at long term follow up. J Clin Epidemiol 1998;51:581-6
30. Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Human Fertil 2000;3:101-5
31. Wild RA. Polycystic ovary syndrome: a risk for coronary artery disease? Am J Obstet Gynecol 2002;186:35-43
32. Elting MW, Korsen TJM, Bezemer PD, Schoemaker J. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow up study of a Dutch PCOS population. Hum Reprod 2001;16:556-60
33. Elting MW, Korsen TJM, Schoemaker J. Obesity rather than menstrual cycle pattern or follicle cohort size, determines hyper-insulinaemia, dyslipidaemia and hypertension in ageing women with polycystic ovary syndrome. Clin Endocrinol 2001;55:767-76
34. Holte J, Gennarelli G, Berne C, et al. Elevated ambulatory daytime blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? Hum Reprod 1996;11:23-8
35. Dahlgren E, Johannson S, Lindstedt G. Women with polycystic ovary syndrome wedge resected in 1956-1965: a long term follow up focusing on natural history and circulating hormones. Fertil Steril 1992;57:505-13
36. Hardiman P, Pillay OS, Atioma W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003;361:1810-12
37. Pillay OC, Te Fong LF, Crow JC, et al. The association between polycystic ovaries and endometrial cancer. Hum Reprod 2006;21:924-9
38. Anderson KE, Sellers TA, Chen PL, et al. Association of Stein-Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa. Cancer 1997;79:494-9
39. Adami S, Zamberlan N, Castello R, et al. Effect of hyperandrogenism and menstrual cycle abnormalities on bone mass and bone turnover in young women. Clin Endocrinol 1998;48:169-73
40. Wilson JMG, Jungner F. Principles and Practice of Screening for Disease. Public Health Paper No. 34. Geneva: World Health Organization, 1968: 163
41. Manson JE, Hsia J, Johnson KC, et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34